Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 10 07 2019
revised: 17 10 2019
accepted: 25 10 2019
pubmed: 11 11 2019
medline: 18 2 2020
entrez: 11 11 2019
Statut: ppublish

Résumé

Surgery is standard treatment for rectal cancer, but neoadjuvant chemoradiation therapy (CRT) may result in clinical complete response (cCR) in select patients, allowing for nonsurgical management (NSM). Prospective studies of NSM strategies are sparse, however, and long-term data on quality of life (QoL) are limited. We conducted a single-arm phase 2 trial of high-dose CRT for NSM of distal rectal cancer; we report secondary long-term patient-reported outcomes (PROs), local regrowth, and overall survival in patients managed nonsurgically. Fifty-one patients with resectable, T2 or T3, N0-N1, low adenocarcinoma received 65 Gy (intensity modulated radiation therapy, brachytherapy boost) and oral tegafur-uracil. Patients with cCR 6 weeks after treatment (clinical examination, magnetic resonance imaging, biopsy) were referred for observation and followed closely with clinical examination, endoscopy, positron emission tomography/computed tomography, and PROs for 5 years. Overall colorectal cancer-specific QoL and specific symptom scores were evaluated at baseline and in follow-up and compared between time points. Local regrowth was estimated using cumulative incidence and overall survival using Kaplan-Meier estimates. Forty patients achieved cCR after treatment; 29 were in follow-up at 24 months, 21 at 36 months, and 20 at 60 months. PRO questionnaire completion rates were 90% at 24 months, 100% at 36 months, and 85% at 60 months for patients still in follow-up. Average QoL score did not differ between baseline (median 11.1) and 24 months (13.7), 48 months (11.1), or 60 months (6.9). Only rectal bleeding deteriorated from baseline, with bowel- and bladder-related symptom scores otherwise unchanged in follow-up. At median follow-up of 5.0 years, local regrowth rate and overall survival were 31% (95% confidence interval, 15%-47%) and 85% (95% confidence interval, 75%-97%), respectively. Long-term follow-up after NSM of distal rectal cancer showed excellent general colorectal cancer QoL and local symptom scores. Our study results indicate that high-dose CRT followed by organ preservation might be an alternative to standard treatment.

Identifiants

pubmed: 31707122
pii: S0360-3016(19)33970-7
doi: 10.1016/j.ijrobp.2019.10.046
pii:
doi:

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

556-563

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Edina Dizdarevic (E)

Department of Oncology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark.

Torben Frøstrup Hansen (T)

Department of Oncology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark; Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark.

John Pløen (J)

Department of Oncology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark; Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark.

Lars Henrik Jensen (L)

Department of Oncology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark; Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark.

Jan Lindebjerg (J)

Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Department of Pathology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark.

Søren Rafaelsen (S)

Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark; Department of Radiology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark.

Anders Jakobsen (A)

Department of Oncology, Vejle Hospital, University of Southern Denmark, Vejle, Denmark; Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Denmark.

Ane Appelt (A)

Danish Colorectal Cancer Center South, Vejle University Hospital, Vejle, Denmark; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH